Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir (Insulin Detemir [rDNA Origin] Injection).

Trial Profile

Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir (Insulin Detemir [rDNA Origin] Injection).

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Insulin detemir (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms PREDICTIVE-303
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jan 2016 Results (post-hoc sub-analysis) published in the Drugs and Aging (n = 2812).
    • 07 Jul 2009 Actual number of patients (5652) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top